Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Immix Biopharma, Inc. has announced a registered offering of 19,117,646 shares of common stock priced at $5.10 per share, aiming to raise approximately $100 million in gross proceeds to support the development of its lead candidate, NXC-201, and for general corporate purposes [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants to purchase 490,196 shares at a price of $5.09 per warrant, with the gross proceeds expected to be $100 million before expenses [1]. - The offering is expected to close on or about December 9, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash and cash equivalents, will be used to fund the development of NXC-201 and for working capital and general corporate purposes [2]. - The company anticipates that these funds will be sufficient to meet operational needs into mid-2027 [2]. Group 3: Company Overview - Immix Biopharma, Inc. is a leader in the treatment of relapsed/refractory AL Amyloidosis, a serious condition caused by toxic light chains produced by the immune system [6]. - The lead candidate, NXC-201, is a CAR-T cell therapy designed to filter out non-specific activation and target the source of toxic light chains [6]. - NXC-201 is currently being evaluated in a multi-center study in the U.S. and has received Regenerative Medicine Advanced Therapy designation from the FDA [6].